Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in inadequately controlled asthma
NCT03944707Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jul 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of remibrutinib in asthma, sponsored by Novartis. Started Jul 2019; status: terminated.
02
Drugs
remibrutinib
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03944707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03944707.